IL-6 Blockade with Clazakizumab is Associated with Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Non-survivors of COVID-19

Clicks: 13
ID: 337388
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #488 of 502 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 502 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: IL-6 inhibitors have been associated with reduced mortality in severe COVID-19 in randomized clinical trials, but the comprehensive immunological impact of IL-6 blockade in the setting of an acute viral infection is poorly understood. METHODS: To gain insight into the systemic immune response to IL-6 inhibition in COVID-19, we utilized samples from patients who participated in a randomized placebo-controlled trial of clazakizumab, a direct anti-IL-6 monoclonal antibody, in severe COVID-19 in the pre-vaccine era. We applied multidimensional measurements of cytokines, chemokines, whole blood transcriptomes, and high-dimensional immune-metabolic flow cytometry to samples before and after treatment to study the changes in immune signatures after IL-6 blockade and to identify pathways associated with positive clinical outcomes. RESULTS: Clazakizumab was associated with a distinct myeloid activation signature and type 2 (T2) cytokine response. Non-survivors who received clazakizumab demonstrated a decoupling of these two clazakizumab-associated phenotypes, exhibiting the most pronounced T2 response coupled with less myeloid activation. Furthermore, elevated baseline levels of the emergency myelopoiesis related cytokine, IL-27, were strongly associated with non-survival after receipt of clazakizumab. CONCLUSIONS: These findings suggest that specific biomarkers may identify patients most likely to benefit from IL-6 blockade and could lead to more personalized applications in COVID-19 and other inflammatory conditions in which IL-6 targeted therapies are in use.
Reference Key
openalex_W7223912499 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Laila Stoddart, Trevor Scott Johnston, Weiqiang Zhou, Ramy El–Diwany, Sherry G. Leung, Nada Alachkar, Russell Wesson, Elizabeth D. Thompson, Andrea L. Cox, Andrew H. Karaba
Are you one of these authors? Claim your profile
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag510
URL
https://doi.org/10.1093/infdis/jiag510
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.